Nivolumab not only failed to ameliorate disease outcomes in patients with newly diagnosed glioblastoma with a methylated or undetermined MGMT promoter subjected to surgery plus adjuvant RT plus temozolomide-based chemotherapy in the context of a randomized phase III CheckMate 548 clinical trial [107] but also failed to outperform temozolomide as a partner for adjuvant RT in patients with newly diagnosed glioblastoma with an unmethylated MGMT promoter in the context of the randomized phase III CheckMate 498 study [108]. Here, MGMT is linked to glioblastoma.